{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:14:36Z","timestamp":1791328476276,"version":"4.3.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0174038","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T15:39:58Z","timestamp":1489678798000},"page":"e0174038","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression"],"prefix":"10.1371","volume":"12","author":[{"given":"Micha\u00ebl","family":"Esquerr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bouillette-Marussig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Goubier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Momot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Gonindard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7202-8844","authenticated-orcid":true,"given":"Marie-Christine","family":"Bissery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"FX Bosch","year":"2002","journal-title":"Journal of clinical pathology"},{"issue":"1 Suppl","key":"ref2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2010.04.002","article-title":"Potential mechanisms for HPV vaccine-induced long-term protection","volume":"118","author":"M Stanley","year":"2010","journal-title":"Gynecologic oncology"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.virol.2008.10.004","article-title":"Interaction of human papillomaviruses with the host immune system: a well evolved relationship","volume":"384","author":"IH Frazer","year":"2009","journal-title":"Virology"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"A Hildesheim","year":"2007","journal-title":"JAMA: the journal of the American Medical Association"},{"issue":"Suppl 5","key":"ref5","doi-asserted-by":"crossref","first-page":"F71","DOI":"10.1016\/j.vaccine.2012.05.091","article-title":"Therapy of human papillomavirus-related disease","volume":"30","author":"PL Stern","year":"2012","journal-title":"Vaccine"},{"issue":"9509","key":"ref6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(06)68181-6","article-title":"Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis","volume":"367","author":"M Kyrgiou","year":"2006","journal-title":"Lancet"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1586\/era.10.89","article-title":"Sexual morbidity following radical hysterectomy for cervical cancer","volume":"10","author":"P Vrzackova","year":"2010","journal-title":"Expert review of anticancer therapy"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrurol.2013.323","article-title":"Urological complications after treatment of cervical cancer","volume":"11","author":"EM Wit","year":"2014","journal-title":"Nature reviews Urology"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.coi.2010.12.010","article-title":"Therapeutic vaccination against human papilloma virus induced malignancies","volume":"23","author":"SH van der Burg","year":"2011","journal-title":"Current opinion in immunology"},{"key":"ref10","first-page":"1","article-title":"Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies","author":"P Vici","year":"2016","journal-title":"Expert review of vaccines"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"169 e1","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"JL Brun","year":"2011","journal-title":"American journal of obstetrics and gynecology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2174\/1874357901206010264","article-title":"Therapeutic Human Papillomavirus (HPV) Vaccines: A Novel Approach","volume":"6","author":"K Kawana","year":"2012","journal-title":"Open Virology Journal"},{"issue":"Suppl 5","key":"ref13","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1016\/j.vaccine.2012.04.106","article-title":"Human papillomavirus vaccines\u2014immune responses","volume":"30","author":"M Stanley","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/erv.13.23","article-title":"Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer","volume":"12","author":"MP Morrow","year":"2013","journal-title":"Expert review of vaccines"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/vaccines2020422","article-title":"Therapeutic Vaccine Strategies against Human Papillomavirus","volume":"2","author":"H Khallouf","year":"2014","journal-title":"Vaccines"},{"key":"ref16","first-page":"149","article-title":"Control of HPV infection and related cancer through vaccination","volume":"193","author":"NP Tran","year":"2014","journal-title":"Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer"},{"issue":"7\u20138","key":"ref17","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1078\/1438-4221-00291","article-title":"The adenylate cyclase toxin from Bordetella pertussis\u2014a novel promising vehicle for antigen delivery to dendritic cells","volume":"293","author":"M Simsova","year":"2004","journal-title":"International Journal of Medical Microbiology"},{"issue":"18","key":"ref18","doi-asserted-by":"crossref","first-page":"8847","DOI":"10.1158\/0008-5472.CAN-07-0321","article-title":"Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system","volume":"67","author":"P Berraondo","year":"2007","journal-title":"Cancer research"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/0008-5472.641.65.2","article-title":"Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein","volume":"65","author":"X Preville","year":"2005","journal-title":"Cancer research"},{"key":"ref20","article-title":"GTL001, a therapeutic vaccine for women infected with human papillomavirus 16 or 18 and normal cervical cytology: results of a phase 1 clinical trial","author":"P Van Damme","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4049\/jimmunol.171.1.27","article-title":"Cutting edge: rapid in vivo killing by memory CD8 T cells","volume":"171","author":"DL Barber","year":"2003","journal-title":"J Immunol"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.4049\/jimmunol.1302974","article-title":"Antigen targeting to CD11b+ dendritic cells in association with TLR4\/TRIF signaling promotes strong CD8+ T cell responses","volume":"193","author":"G Dadaglio","year":"2014","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"ref23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","article-title":"Imiquimod: mode of action","volume":"157","author":"MP Schon","year":"2007","journal-title":"The British journal of dermatology"},{"issue":"9","key":"ref24","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells","volume":"23","author":"MC Feltkamp","year":"1993","journal-title":"European journal of immunology"},{"key":"ref25","unstructured":"Preville X, Leclerc C, Ladant D, Timmerman B, inventorsRecombinant protein carrying human papillomavirus epitopes inserted in adenylate cyclase protein or fragment thereof. Therapeutic uses thereof2005."},{"issue":"1","key":"ref26","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"KY Lin","year":"1996","journal-title":"Cancer research"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/intimm\/dxg144","article-title":"Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes","volume":"15","author":"G Dadaglio","year":"2003","journal-title":"International immunology"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.4049\/jimmunol.173.10.6089","article-title":"Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming","volume":"173","author":"G Schlecht","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.4049\/jimmunol.174.5.2476","article-title":"Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod","volume":"174","author":"G Rechtsteiner","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4049\/jimmunol.181.1.776","article-title":"Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant","volume":"181","author":"S Adams","year":"2008","journal-title":"J Immunol"},{"issue":"6813","key":"ref31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"H Hemmi","year":"2000","journal-title":"Nature"},{"issue":"12","key":"ref32","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nri1246","article-title":"Dendritic-cell control of pathogen-driven T-cell polarization","volume":"3","author":"ML Kapsenberg","year":"2003","journal-title":"Nature reviews Immunology"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"T Kawai","year":"2010","journal-title":"Nature immunology"},{"issue":"8","key":"ref34","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1002\/eji.201344094","article-title":"Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming","volume":"44","author":"CM Fehres","year":"2014","journal-title":"European journal of immunology"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/OLQ.0b013e31815ea8d1","article-title":"Optimal frequency of imiquimod (aldara) 5% cream for the treatment of external genital warts in immunocompetent adults: a meta-analysis","volume":"35","author":"EP Gotovtseva","year":"2008","journal-title":"Sexually transmitted diseases"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0174038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T11:30:52Z","timestamp":1658835052000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0174038"}},"subtitle":[],"editor":[{"given":"Craig","family":"Meyers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0174038","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]}}}